Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stage Small Cell Lung Cancer Using the National Cancer Database

被引:53
作者
Wong, Andrew T. [1 ,2 ]
Rineer, Justin [3 ]
Schwartz, David [1 ,2 ]
Schreiber, David [1 ,2 ]
机构
[1] New York Harbor Healthcare Syst, Dept Vet Affairs, Brooklyn, NY USA
[2] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[3] Univ Florida, Hlth Canc Ctr Orlando Hlth, Orlando, FL USA
关键词
National Cancer Database; Postoperative radiation therapy; Small cell lung cancer; SURGICAL RESECTION; ADJUVANT CHEMOTHERAPY; RADIOTHERAPY; SURGERY; SURVIVAL; DISEASE; CARCINOMA; TRIAL; TIME;
D O I
10.1016/j.jtho.2015.10.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Surgical resection is being increasingly used for early-stage small cell lung cancer (SCLC). However, there are sparse data regarding the role of adjuvant therapies, particularly postoperative radiation therapy (PORT). We investigated the impact of PORT on survival after complete surgical resection for SCLC using the National Cancer Database. Methods: There were 3017 patients diagnosed with non metastatic SCLC between 1998 and 2011 who underwent R0 sublobar resection, lobectomy, or pneumonectomy. Patients were stratified by the use of PORT, and only those who received a minimum dose of 45 Gy were included. The overall survival (OS) of patients based on PORT use were analyzed by Kaplan-Meier analysis and compared using the log-rank test. Multivariate Cox regression analysis was used to identify factors associated with survival. Results: For the entire study population, the 5-year OS was significantly poorer with the addition of PORT (33.9% versus 40.6%; p = 0.005). When analyzed by subgroup, patients with pN0 stage had significantly decreased OS with PORT (39.3% versus 46.3%; p = 0.07) and patients with pN2 stage had significantly improved OS with PORT (29.0% versus 18.6%; p < 0.001). No differences in OS were observed in patients with pN1 stage. On multivariate analysis, the hazard ratio for PORT in pN0 disease was 1.36 (95% confidence interval, 1.09-1.70; p < 0.001) and the hazard ratio for PORT in pN2 disease was 0.60 (95% confidence interval, 0.45-0.80; p < 0.001). Conclusion: The use of PORT was associated with a deleterious effect on OS in patients with pN0 disease but significantly improved OS in patients with pN2 disease. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 22 条
[1]  
[Anonymous], POST RAD NONSM CELL
[2]  
[Anonymous], 2008, SMALL CELL LUNG CANC
[3]   Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come [J].
Brock, MV ;
Hooker, CM ;
Syphard, JE ;
Westra, W ;
Xu, L ;
Alberg, AJ ;
Mason, D ;
Baylin, SB ;
Herman, JG ;
Yung, RC ;
Brahmer, J ;
Rudin, CM ;
Ettinger, DS ;
Yang, SC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 129 (01) :64-72
[4]   Impact of postoperative radiation therapy on survival in patients with complete resection and Stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Riggi, Marcello ;
Hurteloup, Patrick ;
Mahe, Marc-Andre .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (03) :695-701
[5]  
FOX W, 1973, LANCET, V2, P63
[6]   Results of Surgical Treatment for Patients with Small Cell Lung Cancer [J].
Hanagiri, Takeshi ;
Sugio, Kenji ;
Baba, Tetsuro ;
Ichiki, Yoshinobu ;
Yasuda, Manabu ;
Uramoto, Hidetaka ;
Ohga, Takefumi ;
Takenoyama, Mitsuhiro ;
Yasumoto, Kosei .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (08) :964-968
[7]   A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer [J].
Harris, Jeremy P. ;
Murphy, James D. ;
Hanlon, Alexandra L. ;
Quynh-Thu Le ;
Loo, Billy W., Jr. ;
Diehn, Maximilian .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04) :872-884
[8]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]
[9]   A PROSPECTIVE RANDOMIZED TRIAL TO DETERMINE THE BENEFIT OF SURGICAL RESECTION OF RESIDUAL DISEASE FOLLOWING RESPONSE OF SMALL-CELL LUNG-CANCER TO COMBINATION CHEMOTHERAPY [J].
LAD, T ;
PIANTADOSI, S ;
THOMAS, P ;
PAYNE, D ;
RUCKDESCHEL, J ;
GIACCONE, G .
CHEST, 1994, 106 (06) :S320-S323
[10]   The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer Time to Reevaluate [J].
Lim, Eric ;
Belcher, Elizabeth ;
Khoong, Yoon ;
Nicholson, Andrew G. ;
Goldstraw, Peter .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) :1267-1271